CME: Molecular Profiling, Precision Medicine, & Targeted Therapies for the Treatment of ALK Positive NSCLC

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Molecular Profiling, Precision Medicine, & Targeted Therapies for the Treatment of ALK Positive NSCLC

Program Information
Molecular Profiling, Precision Medicine, & Targeted Therapies for the Treatment of ALK Positive NSCLC
Lung cancer continues to be the leading cause of cancer death in the U.S. Approximately 5% of patients with NSCLC have ALK gene rearrangements.

Available credits: 0.75

Time to complete: 45 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, ROS1 rearrangements, and BRAF V600E mutations has led to an improvement in overall survival and progression-free survival in non–small cell lung cancer (NSCLC) by identifying subgroups of patients who benefit from targeted treatment. Approximately 5% of patients with NSCLC have ALK gene rearrangements. One of the most noteworthy areas of progress is the development of effective ALK-targeting therapies to treat NSCLC, including crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib, with additional agents under development in ALK positive advanced NSCLC.

    This activity will review ALK testing, current and emerging treatment options for ALK positive NSCLC, and recognition and management of adverse events associated with these treatments.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Describe how the results of molecular testing can help guide the selection of therapeutic options for ALK positive non–small cell lung cancer
    • Differentiate the mechanism of action, efficacy, and side effect profile of available therapies for ALK positive non–small cell lung cancer
    • Develop management approaches for side effects that can occur with ALK inhibitors
  • Target Audience

    This activity is intended for thoracic oncologists, medical oncologists, pulmonologists, pathologists, physician assistants, oncology nurses, pharmacists, and other healthcare professionals who manage lung cancer. 

  • Disclosure of Conflicts of Interest

    Disclosure of Conflicts of Interest

    AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    Alice T. Shaw, MD, PhD

    Alice T. Shaw, MD, PhD, reported a financial interest/relationship or affiliation in the form of Advisor, Daiichi-Sankyo, Inc, Endo Pharmaceuticals, Genentech, Inc, Novartis Pharmaceuticals Corp, Pfizer, Inc, Roche, Takeda, Blueprint Medicines, Ignyta, Ariad Pharmaceuticals, Inc, Loxo Oncology, Natera, KSQ, Foundation MEd; Research support, Pfizer, Inc, Novartis Pharmaceuticals Corp, Genentech/Roche

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    The following AXIS planners and managers, Jocelyn Timko, BS and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Linda Gracie-King, MS, reports her spouse has a financial interest/relationship or affiliation in the form of Common stock:Exelixis.

  • Accreditation and Credit Designation Statement


    Accreditation Statement

     In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credit Designation for Physicians

    AXIS Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants

     AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 10/29/2019. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists

    This knowledge-based activity is approved for 0.75 contact hours of continuing pharmacy education credit JA4008106-0000-18-034-H01-P.

    Credit Designation for Nursing

    AXIS Medical Education designates this continuing nursing education activity for 0.75 contact hours.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    AXIS Contact Information

    For information about the certification of this activity, please contact AXIS at

  • Provider

    Provided by 

  • Commercial Support

    Supported by an educational grant from Genentech.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Method of Participation and Request for Credit

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

    There is no fee for this educational activity.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio


Programs 10/19/19

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.